Literature DB >> 21718055

Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.

Rajendra P Tanpure1, Benson L Nguyen, Tracy E Strecker, Savannah Aguirre, Suman Sharma, David J Chaplin, Bronwyn G Siim, Ernest Hamel, John W Lippert, George R Pettit, Mary Lynn Trawick, Kevin G Pinney.   

Abstract

The natural products combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are potent cancer vascular disrupting agents and inhibitors of tubulin assembly (IC₅₀ = 1-2 μM). The phosphorylated prodrugs CA4P and CA1P are undergoing human clinical trials against cancer. CA1 is unique due to its incorporation of a vicinal phenol, which has afforded the opportunity to prepare both diphosphate and regioisomeric monophosphate derivatives. Here, we describe the first synthetic routes suitable for the regiospecific preparation of the CA1-monophosphates CA1MPA (8a/b) and CA1MPB (4a/b). The essential regiochemistry necessary to distinguish between the two vicinal phenolic groups was accomplished with a tosyl protecting group strategy. Each of the four monophosphate analogues (including Z and E isomers) demonstrated in vitro cytotoxicity against selected human cancer cell lines comparable to their corresponding diphosphate congeners. Furthermore, Z-CA1MPA (8a) and Z-CA1MPB (4a) were inactive as inhibitors of tubulin assembly (IC₅₀ > 40 μM), as anticipated in this pure protein assay.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718055      PMCID: PMC3275140          DOI: 10.1021/np200104t

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  32 in total

Review 1.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.

Authors:  C M Lin; H H Ho; G R Pettit; E Hamel
Journal:  Biochemistry       Date:  1989-08-22       Impact factor: 3.162

3.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

Authors:  G R Pettit; S B Singh; E Hamel; C M Lin; D S Alberts; D Garcia-Kendall
Journal:  Experientia       Date:  1989-02-15

4.  Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug.

Authors:  G R Pettit; M P Grealish; D L Herald; M R Boyd; E Hamel; R K Pettit
Journal:  J Med Chem       Date:  2000-07-13       Impact factor: 7.446

5.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

6.  Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.

Authors:  Ian G Kirwan; Paul M Loadman; David J Swaine; D Alan Anthoney; George R Pettit; John W Lippert; Steve D Shnyder; Patricia A Cooper; Mike C Bibby
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

7.  Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.

Authors:  G R Pettit; S B Singh; M L Niven; E Hamel; J M Schmidt
Journal:  J Nat Prod       Date:  1987 Jan-Feb       Impact factor: 4.050

8.  Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.

Authors:  C M Lin; S B Singh; P S Chu; R O Dempcy; J M Schmidt; G R Pettit; E Hamel
Journal:  Mol Pharmacol       Date:  1988-08       Impact factor: 4.436

9.  Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

Authors:  Jianyi Hua; Yezhou Sheng; Kevin G Pinney; Charles M Garner; Robert R Kane; Joseph A Prezioso; George R Pettit; David J Chaplin; Klaus Edvardsen
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

10.  In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.

Authors:  K Grosios; S E Holwell; A T McGown; G R Pettit; M C Bibby
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  5 in total

1.  Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.

Authors:  Christine A Herdman; Tracy E Strecker; Rajendra P Tanpure; Zhi Chen; Alex Winters; Jeni Gerberich; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2016-09-22       Impact factor: 3.597

2.  Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.

Authors:  Casey J Maguire; Zhi Chen; Vani P Mocharla; Madhavi Sriram; Tracy E Strecker; Ernest Hamel; Heling Zhou; Ramona Lopez; Yifan Wang; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2018-08-24       Impact factor: 3.597

3.  Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.

Authors:  Laxman Devkota; Chen-Ming Lin; Tracy E Strecker; Yifan Wang; Justin K Tidmore; Zhi Chen; Rajsekhar Guddneppanavar; Christopher J Jelinek; Ramona Lopez; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2016-01-06       Impact factor: 3.641

4.  Access to a Structurally Complex Compound Collection via Ring Distortion of the Alkaloid Sinomenine.

Authors:  Alfredo Garcia; Bryon S Drown; Paul J Hergenrother
Journal:  Org Lett       Date:  2016-09-21       Impact factor: 6.005

5.  Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Authors:  Blake A Winn; Laxman Devkota; Bunnarack Kuch; Matthew T MacDonough; Tracy E Strecker; Yifan Wang; Zhe Shi; Jeni L Gerberich; Deboprosad Mondal; Alejandro J Ramirez; Ernest Hamel; David J Chaplin; Peter Davis; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2020-03-20       Impact factor: 4.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.